--- title: "Weekly Recap | Alaunos Therapeutics -9.17%, registered direct offering lands" type: "News" locale: "en" url: "https://longbridge.com/en/news/300191968.md" description: "Alaunos Therapeutics (TCRT) lost 9.17% this week to close at $1.09, while the S&P 500 gained 1.21%, leaving the stock roughly 10.38 percentage points behind the benchmark. It was a pullback after an early pop: the stock opened Monday at $1.26 and touched $1.35 intraday, held near $1.27 on Tuesday, then drifted lower each day to finish at $1.09 on Friday, the low end of the week. Weekly amplitude was 21.43%." datetime: "2026-09-26T07:09:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/300191968.md) - [en](https://longbridge.com/en/news/300191968.md) - [zh-HK](https://longbridge.com/zh-HK/news/300191968.md) generator: "portal-rs" --- # Weekly Recap | Alaunos Therapeutics -9.17%, registered direct offering lands ## The Week Alaunos Therapeutics (TCRT) lost 9.17% this week to close at $1.09, while the S&P 500 gained 1.21%, leaving the stock roughly 10.38 percentage points behind the benchmark. It was a pullback after an early pop: the stock opened Monday at $1.26 and touched $1.35 intraday, held near $1.27 on Tuesday, then drifted lower each day to finish at $1.09 on Friday, the low end of the week. Weekly amplitude was 21.43%. ## Key Events The week’s main development landed on Wednesday, when Alaunos announced a securities purchase agreement with accredited investors and a new registered direct offering. Monday’s pre-market note had already flagged financing and charter amendments, and the company filed a 424B3 on Tuesday to lay the groundwork. Intraday moves were choppy: the stock rose 5.00% in overnight trading Monday, fell 3.33% pre-market the same day, then slipped another 3.17% overnight Tuesday, suggesting the market digested the financing news with some hesitation. ## Analyst Ratings One covering broker currently rates the stock hold, with a consensus rating of hold. The consensus target price is $205.4999, which sits about 18,753.20% above the current price of $1.09. With only one rating in the set, there is no dispersion to read. The rating data was last updated on 15 February 2024, and industry ranking data is not disclosed. ## The Week Ahead Next week brings a run of US macro readings: the Dallas Fed manufacturing business activity index on Monday, followed on Tuesday by FHFA house prices, the Case Shiller 20-city home price index, JOLTS job openings and consumer confidence. For Alaunos, the near-term watch is the pace of funding after this week’s securities purchase agreement and registered direct offering, and how the stock responds to the dilution story. ## In Short The tension this week: Alaunos pushed ahead with financing and charter changes, yet the stock faded after an early surge and closed the week down 9.17%. The price-to-book ratio is about 4.25x, and the latest session’s flow shows small and medium orders roughly balanced, with no large-order direction. The next question is how the registered direct offering plays out and whether prices can hold above the week’s low. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [TCRT.US](https://longbridge.com/en/quote/TCRT.US.md) ## Related News & Research - [Alaunos Acquires Velaris and Secures Major Financing](https://longbridge.com/en/news/301727995.md) - [Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics | TCRT Stock News](https://longbridge.com/en/news/301727829.md) - [GE Vernova Stock Is Taking a Hit – What's Driving the Selloff and What Wall Street Sees Next](https://longbridge.com/en/news/302747785.md) - [Western Digital Earnings Preview: Revenue Expected to Rise 47%, Highest Wall Street Price Target at $900](https://longbridge.com/en/news/302668441.md) - [Micron announces a new profit-sharing program](https://longbridge.com/en/news/302750416.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**